Riluzole
Treatment for Motor Neuron Disease
Typical Dosage: 50 mg twice daily
Effectiveness
45%
Safety Score
65%
Clinical Trials
43
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
50 mg twice daily
Time to Effect
6-12 months for survival benefit
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$200
Side Effect Mgmt:$100
Total Annual:$2,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.1
Riluzole Outcomes
for Motor Neuron Disease
Efficacy Outcomes
Overall Effectiveness
+45%
Common Side Effects
Nausea
+20%
Asthenia
+14%
Liver enzyme elevation (>3x ULN)
+15%
Dizziness
+11%
Active Clinical Trials
3 active trials recruiting for Riluzole in Motor Neuron Disease
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
NCT07093268NOT YET RECRUITINGPHASE1
10 participants
INTERVENTIONAL
Birtinya, Australia +1 more
Started: Aug 15, 2025
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267RECRUITINGPHASE3
495 participants
INTERVENTIONAL
Birmingham, United States +55 more
Started: Feb 2, 2021
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS
NCT04745299ACTIVE NOT RECRUITINGPHASE3
115 participants
INTERVENTIONAL
Yangsan, South Korea +4 more
Started: Mar 23, 2021
Completed Clinical Trials
11 completed trials for Riluzole in Motor Neuron Disease
Tamoxifen Treatment in Patients With Motor Neuron Disease
NCT02166944COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
New Taipei City, Taiwan
Started: Apr 1, 2014
CARE Canadian ALS Riluzole Evaluation
NCT00542412COMPLETEDPHASE4
414 participants
INTERVENTIONAL
Laval, Canada
Started: Jan 1, 2001
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
NCT05508074COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Bron, France +8 more
Started: Dec 2, 2022
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS
NCT06676423COMPLETEDPHASE1
8 participants
INTERVENTIONAL
Seoul, South Korea
Started: Nov 9, 2022
Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis
NCT04454840COMPLETEDEARLY_PHASE1
20 participants
INTERVENTIONAL
Beijing, China
Started: May 1, 2016
Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
NCT00353665COMPLETEDPHASE2, PHASE3
63 participants
INTERVENTIONAL
Lisbon, Portugal
Started: Jul 1, 2005
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
NCT00868166COMPLETEDPHASE3
512 participants
INTERVENTIONAL
Leuven, Belgium +14 more
Started: Apr 30, 2009
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
NCT02645461COMPLETEDNA
50 participants
INTERVENTIONAL
Started: Jan 1, 2014
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
NCT03520517COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Fort Lauderdale, United States +4 more
Started: Feb 2, 2018
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
NCT01709149COMPLETEDPHASE2
711 participants
INTERVENTIONAL
Phoenix, United States +74 more
Started: Oct 1, 2012
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT02238626COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Charlotte, United States
Started: Sep 1, 2014
Showing 20 of 43 total trials